Promising novel antiangiogenic strategies are emerging for the treatment of cancer
and the inhibition of angiogenesis might represent a powerful tool as adjuvant therapy of
malignant tumors. Over the last fifteen years several reports have been published concerning
the relationship between tumor progression and angiogenesis in neuroblastoma in experimental
models in vitro and in vivo. Moreover, a high vascular index in neuroblastoma correlates with
poor prognosis, suggesting dependence of aggressive tumor growth on active angiogenesis.
Here, we present an overview of the most recent advances in antiangiogenesis in
neuroblastoma, and describe tumor vascular-targeted preclinical results, as well as future
perspectives.
